...
首页> 外文期刊>Current opinion in endocrinology, diabetes, and obesity >Molecular markers of aggressiveness of thyroid cancer.
【24h】

Molecular markers of aggressiveness of thyroid cancer.

机译:甲状腺癌侵袭性的分子标记。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE OF REVIEW: To review recent progress at defining molecular markers that predict the biological behavior of thyroid cancer. RECENT FINDINGS: Thyroid cancer behavior is defined by the effects of the initiating oncogene as well as secondary events in tumor cells and the tumor microenvironment that are both genetic and epigenetic. Over the past several years, there has been intense focus on identifying molecular markers to better predict the aggressiveness of thyroid cancers and also to define therapeutic targets. The results of recent articles in this area of work are summarized with a focus of differentiated follicular-cell-derived forms of thyroid cancer. SUMMARY: Clinical staging predicts tumor behavior in many cases, but does not allow true 'personalization' of initial therapy or identify potential therapeutic targets for patients with progressive disease that does not respond to standard therapies. Recent data point to several new opportunities to refine thyroid cancer treatment based on molecular information. Several highlighted articles have begun to apply this information with clinical intent.
机译:审查目的:审查在定义可预测甲状腺癌生物学行为的分子标记物方面的最新进展。最近的发现:甲状腺癌的行为是由始发癌基因的影响以及遗传和表观遗传的肿瘤细胞和肿瘤微环境中的继发事件所决定的。在过去的几年中,人们一直非常关注识别分子标记物,以更好地预测甲状腺癌的侵袭性并确定治疗靶标。总结了在该工作领域中最新文章的结果,重点是分化的滤泡细胞衍生形式的甲状腺癌。摘要:临床分期可在许多情况下预测肿瘤行为,但不能真正实现初始治疗的“个性化”,也不能确定对标准疗法无反应的进行性疾病患者的潜在治疗靶标。最近的数据指出了基于分子信息改进甲状腺癌治疗的若干新机会。几篇重点文章已开始出于临床目的应用这些信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号